title: N-Acetylcysteine for thrombotic thrombocytopenic purpura: is a von Willebrand factor-inhibitory dose feasible in vivo?
authors.affiliation: Monash Haematology, Monash University, Clayton, Victoria, Australia; Southern Clinical School, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Victoria, Australia. jake.shortt@monashhealth.org.
authors.forename: Jake
authors.initials: J
authors.lastname: Shortt
authors.forename: Stephen S
authors.initials: SS
authors.lastname: Opat
authors.forename: Erica M
authors.initials: EM
authors.lastname: Wood
mesh_terms: D000111:Acetylcysteine / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D011697:Purpura, Thrombotic Thrombocytopenic / Q000188:drug therapy*
chemical_list: D000111:Acetylcysteine